
The discovery of an ‘inflamed yet suppressed’ immune state in liver cancer helps explain why traditional immunotherapy predictors like tumor mutational burden often fail in high-RPA cases. This finding emerges from a recent comprehensive pan-cancer evaluation published in the Egyptian Liver Journal, which identifies the Replication Protein A (RPA) family as a significant indicator of poor prognosis. By leveraging expansive










